Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Summary not available.